RxDoctor Payments DataLook up a doctor →

Justin Brown, NP

Family · Fort Wayne, INNPI 1134358005

Payments from drug & device makers

$141,902in general payments, 2019–2025

Across 934 payments — averaging $151.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Corcept Therapeutics$86K
  • Novo Nordisk$41K
  • AstraZeneca$6K
  • Lilly USA, LLC$1K
  • Abbott$769
  • Tandem Diabetes Care, Inc.$735
  • plus $6K from 42 others

What the payments were for

  • Speaking & faculty fees$108,10476%
  • Travel & lodging$16,21411%
  • Food & beverage$17,51712%
  • Education$670%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$141,902 in reported general payments places this provider in the 95th percentile of 4,392 family providers in Indiana.

See all family providers in Indiana

Medicare billing

Part B allowed, 2024
$103,092
Medicare patients
389
Services billed
1,907

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide303$488,340
KorlymMifepristone21$474,965
MounjaroTirzepatide201$262,620
Xultophy 100-3.6Insulin Degludec/Liraglutide122$235,747
JardianceEmpagliflozin110$125,582
Tresiba Flextouch U-200Insulin Degludec82$118,908
FarxigaDapagliflozin Propanediol72$79,752
Humalog Kwikpen U-200Insulin Lispro20$68,024
Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/737$66,025
Soliqua 100-33Insulin Glargine/Lixisenatide42$57,821
TrulicityDulaglutide29$50,293
RybelsusSemaglutide24$45,241
Xigduo XrDapaglifloz Propaned/Metformin38$43,830
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog64$37,954
Fiasp FlextouchInsulin Aspart (Niacinamide)21$36,016

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Xultophy 100-3.6, Rybelsus, Fiasp, Novolog$40,971$806,717503 claims
Corcept TherapeuticsKorlym$86,413$474,96521 claims
Lilly USA, LLCMounjaro, Trulicity, Humalog$1,089$339,559309 claims
Boehringer IngelheimJardiance, Synjardy Xr, Synjardy, Glyxambi$573$178,101167 claims
AstraZenecaFarxiga$5,819$79,75272 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$400$57,82142 claims
AbbVieSynthroid$273$10,381106 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$102$3,643379 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,392 family providers in Indiana.

Other family in Fort Wayne

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →